#clinical trials vn

[satasfries]

Sorry i was gone i have decided i wanna revamp my style by relearning some stuff so on blahblah anyway i decided to watch MBH playthru of Clinical Trials and I am sorry but I am whipped for Lee he's mentally ill and whined so I was struck with inspiration

[ratkingah]

I made stickkerss

[paceytest]

the nurses angel

[bitronic]

[soupky]

i reallly like this game can you tell…I LOVE ANGEL AND LEEE

[angel-came-to-visit]

Today i bring you Angel doodles. Tomorrow? Likely more hehe

[swirliesweets]

Clinical Trial comic featuring a prompt from Incorrect Quotes lol

[angelislix]

the angelito …

[credenceresearchdotblog]

The global Vagus Nerve Stimulator Market is projected to grow from USD 510.2 million in 2023 to an estimated USD 1,201.43 million by 2032, reflecting a robust compound annual growth rate (CAGR) of 11.3% from 2024 to 2032. The vagus nerve stimulator (VNS) market has been gaining significant traction over the past few years, driven by advancements in medical technology, increasing awareness of neurological disorders, and the growing prevalence of treatment-resistant diseases. This article delves into the current market landscape, its key drivers, challenges, and future opportunities.

Browse the full report https://www.credenceresearch.com/report/vagus-nerve-stimulator-market

Understanding Vagus Nerve Stimulation

The vagus nerve, one of the longest cranial nerves in the human body, plays a crucial role in regulating involuntary body functions such as heart rate, digestion, and mood. Vagus nerve stimulation involves the use of electrical impulses to modulate its activity, providing therapeutic benefits for various conditions. VNS devices are either implantable or non-invasive, offering tailored solutions for medical practitioners and patients alike.

Market Drivers

1. Rising Prevalence of Neurological and Psychiatric Disorders Neurological conditions such as epilepsy, depression, and anxiety disorders have been on the rise globally. According to the World Health Organization (WHO), approximately 50 million people worldwide suffer from epilepsy, many of whom are resistant to conventional treatments. VNS has proven to be a viable alternative for such cases, propelling its market demand.

2. Expanding Applications in Chronic Diseases Beyond epilepsy and depression, VNS is being explored for other conditions, including migraines, Alzheimer's disease, and inflammatory disorders. This broadening application base is a significant factor driving market growth.

3. Technological Advancements The development of non-invasive VNS devices has transformed the landscape, providing patients with safer, more accessible options. Innovations such as wireless and wearable devices have further enhanced convenience and compliance.

4. Growing Awareness and Investment Increased awareness of the benefits of VNS among healthcare providers and patients, coupled with investments from governments and private organizations, has spurred market expansion. Clinical trials and research funding have also played a pivotal role in uncovering new applications for VNS technology.

Market Challenges

1. High Costs and Limited Reimbursement Policies The cost of VNS devices and implantation procedures can be prohibitive, especially in developing economies. Additionally, inadequate reimbursement frameworks hinder accessibility, limiting market penetration.

2. Risk of Side Effects While VNS is generally considered safe, potential side effects such as hoarseness, throat pain, and breathing difficulties can deter patients from opting for the treatment.

3. Regulatory Hurdles Stringent regulatory requirements for medical device approval can delay the launch of innovative products, impacting market growth.

Future Outlook

The vagus nerve stimulator market is poised for sustained growth, driven by ongoing research and development, technological innovations, and expanding therapeutic applications. Strategic collaborations between key players, healthcare providers, and research institutions are expected to unlock new opportunities.

Key players

Soterix Medical Inc.

MicroTransponder Inc.

Beijing PINS Medical Co., Ltd.

SetPoint Medical Corporation

Parasym Ltd

tVNS Health GmbH

Neuropix Company Ltd.

electroCore, Inc.

LivaNova PLC

Segments

Based on Product

Implantable VNS devices

External VNS devices

Based on Application

Epilepsy

Depression

Others

Based on End User

Hospitals

Neurology clinics

Others

Based on Region

North America

U.S.

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Spain

Rest of Europe

Asia Pacific

China

Japan

India

South Korea

South-east Asia

Rest of Asia Pacific

Latin America

Brazil

Argentina

Rest of Latin America

Middle East & Africa

GCC Countries

South Africa

Rest of the Middle East and Africa

Browse the full report https://www.credenceresearch.com/report/vagus-nerve-stimulator-market

Contact:

Credence Research

Please contact us at +91 6232 49 3207

Email: sales@credenceresearch.com

Website: www.credenceresearch.com

[tritonmarketresearchamey]

Epilepsy Devices Market: Tech Trends 2022-2028

According to the WHO, epilepsy is a chronic brain disorder that affects 50 million individuals, making it one of the most prevalent neurological conditions worldwide. It is estimated that with access to early detection and appropriate care, 70% of the population diagnosed with epilepsy may live seizure-free. According to our estimates, the global epilepsy devices market was valued at $669.73 million in 2021 and is expected to reach $1157.58 million by 2028, growing at a CAGR of 8.16% during the forecast period 2022-2028.

Government institutions worldwide are focused on starting initiatives to create innovative epilepsy devices with AI and machine learning integration. Additionally, organizations that support research need to encourage high-quality comparative efficacy trials and sufficient data to guide therapeutic practice in epilepsy. As a result of these technologically advanced equipment and increasing drug trials, the market for epilepsy devices is anticipated to grow throughout the forecast period.

Epilepsy Devices - Key Detection Methodologies

Currently, several wearable technologies can detect seizures, collect data, and alert caregivers. Although with technological advancements, the ability to detect seizure-related alterations increases. Top trends backing this tech boom include:

Wearable devices are estimated to be the fastest-growing device type during the forecast period. Monitoring epileptic patients is crucial, as 20% of epileptics only have seizures while asleep, 40% only have seizures while awake, and 35% have seizures both when they are awake and asleep. With technologically advanced non-invasive wearable sensors, measuring accelerometry, photoplethysmography (PPG), electrodermal activity (EDA), electromyography (EMG), and other signals outside of the conventional clinical environment have become effective.

Vagus Nerve Stimulation (VNS) has emerged as the fastest-growing application category. VNS Therapy has been approved by the U.S. Food and Drug Administration (FDA) as an add-on therapy for age 4 years and above to treat drug-resistant epilepsy or refractory epilepsy. VNS has been reportedly beneficial in many patients, including the ones with posttraumatic epilepsy (PTE). PTE is a common consequence of traumatic brain injury and accounts for about 20% of symptomatic epilepsy cases.

As per estimates, Electroencephalography lead the detection and prediction devices type segment in 2021 and is expected to maintain its stronghold during the forecast period. There is growing interest in wearable or mobile EEG solutions that allow long‐term EEG monitoring in an easy‐to‐use format. Despite the availability of these new EEG solutions, their adoption is still limited in clinical practice, mainly because of the unfamiliarity of healthcare and biomedical research sectors with the technology and its application.

Strategic Initiatives and Government Approvals

Different end-users, such as homecare settings, hospitals, and clinics, are utilizing epilepsy devices. The manufacturers of epilepsy monitoring devices are likely to gain prominent business opportunities from the hospital & clinics segment owing to the rise in the use of EEG monitoring and emergency medical services.

The government authorities of several developing nations, including India and China, are focusing on developing sturdy healthcare infrastructure. As a result, operating players are expected to gain sizable growth prospects in the region during the forecast period. Owing to this, the Asia Pacific epilepsy devices market is anticipated to witness the fastest growth with a CAGR of 8.38% throughout the forecast period.

In addition, companies are also focusing on launching novel devices for children. Moreover, companies are also using organic and inorganic strategies, including mergers and acquisitions, to stay ahead of the competition. Some of these include:

In September 2022, Boston Scientific Corporation’s current-generation WATCHMAN FLX™ Left Atrial Appendage Closure (LAAC) Device received U.S. Food and Drug Administration (FDA) approval to expand the instructions for use labeling. The company also received FDA 510(k) clearance for the EMBOLD Fibered Detachable Coil, which reduces the blood flow rate in the peripheral vasculature.

In July 2022, Medtronic PLC received FDA 510(k) clearance for its UNiD Spine Analyzer v4.0 planning platform to leverage machine learning.

In November 2021, NeuroPace, Inc. received an Investigational Device Exemption (IDE) from the FDA to study the company’s RNS System to treat primary generalized epilepsy in patients aged 12 and above.

Way Forward

With technological advancements, epilepsy detection devices with exceptionally low false alarm rates have recently been developed. They are based on computationally intensive algorithms and employed in implanted systems for pre-surgical monitoring. Recent research has produced encouraging findings for probabilistic seizure risk projections using long-term wearable technology and electronic seizure diaries. The symptoms, mood, and cognitive function of an individual may also have predictive significance. Therefore, technological advances in non-invasive wearable sensors are anticipated to create growth opportunities for the epilepsy devices market.

 

FAQ:

Q1) What are the key end-users of the epilepsy devices market?

The key end-users in the epilepsy devices market include hospitals & clinics, neurology centers, homecare settings, and other end-users.

Q2) Which region leads the global epilepsy devices market?

North America leads the global epilepsy devices market.

[satasfries]

Lee pov </3 i just wanted a silly doodle of them

Additional Angel pov and alt ver

[ratkingah]

Gymbro lee my beloved

[bestneurologistinmumbai]

When it comes to managing and treating seizures, finding a skilled and experienced specialist is crucial. In Mumbai, Dr. Kharkar stands out as a leading name in the field of neurology, particularly for patients seeking advanced seizure treatment. With a comprehensive approach to diagnosis, treatment, and patient care, Dr. Kharkar has established a reputation for excellence.

Expertise and Qualifications

Dr. Kharkar is a board-certified neurologist with specialized training in epileptology, the branch of medicine that deals with the study and treatment of epilepsy and seizure disorders. His extensive education and training, including a residency in neurology and a fellowship in epilepsy, equip him with the knowledge and skills to handle even the most complex seizure cases.

Comprehensive Diagnostic Approach

Dr. Kharkar utilizes state-of-the-art diagnostic tools to accurately diagnose the type and cause of seizures. His diagnostic process includes:

Detailed Patient History: Understanding the patient's medical history, seizure characteristics, and triggers.

Advanced Imaging: MRI and CT scans to identify structural abnormalities in the brain.

Electroencephalogram (EEG): Monitoring electrical activity in the brain to detect abnormal patterns.

Blood Tests: Identifying potential underlying conditions that may contribute to seizures.

Personalized Treatment Plans

Recognizing that every patient is unique, Dr. Kharkar develops personalized treatment plans tailored to individual needs. These plans may include:

Medication Management: Prescribing anti-seizure medications tailored to the specific type of seizure and patient response.

Surgical Options: For patients who do not respond to medication, Dr. Kharkar offers advanced surgical interventions, such as resective surgery or vagus nerve stimulation (VNS).

Lifestyle Modifications: Advising on dietary changes, sleep hygiene, and stress management techniques that can help reduce seizure frequency.

Continuous Monitoring: Using devices like ambulatory EEG to monitor seizures over an extended period and adjust treatment as necessary.

Compassionate Patient Care

Beyond his clinical expertise, Dr. Kharkar is known for his compassionate approach to patient care. He takes the time to listen to his patients, addressing their concerns and providing education about their condition and treatment options. His goal is to empower patients and their families with the knowledge and support they need to manage seizures effectively.

Cutting-Edge Research and Innovation

Dr. Kharkar stays at the forefront of medical research, continually updating his practice with the latest advancements in seizure treatment. His involvement in clinical trials and research ensures that his patients have access to the most innovative therapies available.

Conveniently Located

Dr. Kharkar's clinic is conveniently located in Mumbai, making it accessible for patients from all parts of the city and beyond. His clinic is equipped with modern facilities, ensuring a comfortable and efficient experience for all patients.

For anyone seeking expert care for seizure disorders in Mumbai, Dr. Kharkar offers a combination of advanced medical expertise, personalized treatment plans, and compassionate care, making him the ideal choice for managing and treating seizures effectively.

[enby-opossum]

I also did genetic testing cuz I've been on so many meds (GeneSight in 2016), and the only med I pissed right out was Lamictal. But the biggest insight was learning I had Bipolar type 2 after going manic on Effexor. Got on a mood stabilizer, but it just gave me double depression (which is unfortunately a fucking thing).

The depression was so bad I even tried an MAOI, thinking, "if this doesn't work, I'll do ECT." MAOI didn't work, but then I found a local University was doing a clinical trial for the Vagus Nerve Stimulator Implant (VNS) and did that instead. AND IT WORKS!

And then I figured out I had ADHD. Then Autism. And started ED recovery.

Now I'm currently on the VNS, zonisamide (off label mood stabilizer), Adderall XR (morn) and IR (2pm), and meds for pain management. I might start Buspar again, cuz it was helpful for me in 2020 for 〘the Horrors〙.

(VNS has been approved for depression since 2008, Medicare just wanted to have their own data to decide if they wanted to cover it in the future)

Also past Rx doc buds~★

girls when they have a CYP2C19 genetic defect that effects their ability to metabolize a plethora of medications

[healthcaremarketfmi]

Muscle Stimulation Devices Market Analytical Overview, Growth Factors, Demand, Trends and Forecast to 2028

In 2022, sales of muscle stimulation devices are expected to reach US$ 694.7 Mn. The performance of the global muscle stimulation devices market is expected to witness immensely impactful developments, with potential improvements in the recovery of stroke through nerve stimulation. With rising rate of AIS (acute ischemic stroke), the focus has been shifted to improving the associated stages of stroke care, including prevention, intervention, and rehabilitation. The Ohio State University has been conducting a new clinical trial to shorten the motor skills recovery period in stroke patients, via VNS (vagus nerve stimulation).

Download our Sample Report to discover how recent industry developments, like@ https://www.futuremarketinsights.com/reports/sample/rep-gb-1140

The trial involves the use of a device – Vivistim, which has been developed by MicroTransponder, a Dallas-based company. The device functions by coupling VNS with the muscle movement, during rehabilitation. It is supposed to build up the motor function, learning, and memory, drastically improving the post-stroke outcome thereby. This nerve stimulation therapy, if used in tandem with appropriate interventions, can potentially result in excellent rehabilitation, minimizing the impact of complications that may follow the treatment process. If Vivistim delivers positive results and enables stroke patients to regain their motor function early, the market participants may witness multiple doors of opportunities in the rehabilitative treatment area.

Key Companies to Focus on Strong Distribution Channel Development & Suppliers to Strengthen Presence in Emerging Markets

New and innovative product launches such as wireless devices are being considered by manufacturers as the key to achieve enhanced device capabilities, which is presumed to trigger sales in long term. To expand market shares and improve distribution network through the next decade, several players are prioritizing strategic partnerships, i.e. distribution agreements for their product offerings. Enhanced distribution will also help the stakeholders penetrate various untapped regional markets.

Any Questions, Reach Out To Us @ https://www.futuremarketinsights.com/ask-question/rep-gb-1140

Key players in the global muscle stimulation devices market are focusing on development of new pain management methods and techniques. Adoption of innovative marketing strategy by muscle stimulation device manufacturers is attributed to their gradually increasing market value share. Increased focus on strengthening of distribution channel will reportedly be the key for market expansion in emerging economies. On the flipside, suppliers are likely to consider patient needs as a top priority, while ensuring the supply of high-quality products to end users. Stakeholders are strengthening product portfolio by launching new products with improved features, and through strategic mergers and acquisitions. Moreover, a growing number of local players in the muscle stimulation devices market is expected to result in creating a fragmented market, since the market is already led by smaller-sized firms catering to domestic customer demands.

Muscle Stimulation Devices to Face Passive Growth

Despite immense scope for innovation in product development and applications, the global market for muscle stimulation devices is projected to observe sluggish growth over the next decade. As prompted by a recent research study by Future Market Insights, the global muscle stimulation devices market will expand at a CAGR of 3.9% during 2018-2028, attaining a value of over US$ 870 Mn by 2028 end. High price point will remain a longstanding factor limiting widespread adoption of muscle stimulators. Stringent regulatory norms regarding the launch and use of muscle stimulation devices is also anticipated to hinder market growth in upcoming decade.

By value, North America and Western Europe are expected to represent the dominant markets for muscle stimulation devices, whereas developing economies such as APEJ, Latin America, and Eastern Europe will reportedly exhibit relatively promising performance over the projection period.